Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Stall in weeks 1 through 8 (early treatment) Most likely cause: sub-therapeutic dose
Additionally, after 40 weeks in SURPASS-2, individuals treated with tirzepatide exhibited lower triglyceride levels, ranging from 19.0% to 24.8%, in comparison to semaglutide 1 mg, which showed an 11.5% reduction
Our clinicians can help you find the right medication and prescribe it if needed
We can help you identify and connect with these resources, ensuring you have access to the support you need to manage your treatment costs
If you experience significant side effects, consult your healthcare provider for guidance
A Novo Nordisk spokesperson told Freethink they expect both trials to wrap up in 2025
US$ 29.27
US$ 21.61
US$ 21.71
US$ 22.58
US$ 28.98
US$ 25.60
US$ 21.44
